Welcome to MediciNova

 

MediciNova in the News

National Asthma Awareness Month: What's Next in the Treatment of Acute Asthma?

San Diego's MediciNova Nears Turning Point with Lead Drug for Asthma - May 8, 2012

Click to read about Dr. Iwaki, President & CEO of MediciNova, feautred in PharmaVoice May 2012

Click to watch a segment featuring MN-221 by NBC Philadelphia.

 

NBCMediciNova Featured on NBC's Better Life Guide - Biotech N' You

 

Click for more information on our Core Candidates:

 

MN-221 Update:

March 22 , 2012 - MediciNova, Inc. announced it has completed enrollment in its Phase 2 clinical trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma.

More Information

MN-166 Update:

February 1 , 2012 - MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis.

More Information

 

MediciNova's Corporate Presentation

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market.

More Information

 

 

 

 

 

Order Preliminarily Approving Settlement and Providing for Notice

Medicinova